<DOC>
	<DOCNO>NCT01559155</DOCNO>
	<brief_summary>The primary objective study describe compare plasmatic anti-proteasome auto-antibody concentration among three distinct group : ( 1 ) patient suffer bullous pemphigoide ; ( 2 ) patient suffer dermatological auto-immune disease ; ( 3 ) elderly control group .</brief_summary>
	<brief_title>Role Proteasomes Dermatological Autoimmune Disease : Bullous Pemphigoid</brief_title>
	<detailed_description>The secondary objective study : To compare follow parameter 3 group : - plasmatic proteasome concentration - plasmatic proteasome proteolytic activity To explore potential relationship : - plasmatic proteasome concentration - plasmatic proteasome proteolytic activity - plasmatic anti-proteasome auto-antibody concentration - measure disease severity dermatological auto-immune disease To characterize plasmatic anti-proteasome auto-antibodies patient suffer bullous pemphigoide dermatological auto-immune disease ( bullous auto immune disease : pemphigus , cutaneous lupus , ... ) . To characterize expression activity proteasomes skin sample , plasma circulate mononuclear cell patient bullous pemphigoide .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Dermatologic Agents</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>The patient must give his/her inform sign consent The patient must insure beneficiary health insurance plan The patient take systemic treatment The patient treat topical steroid 15 day . For bullous pemphigoid group : clinical sign : erythematousbased lesion , especially flexion area arm leg , afflict mucous membrane , without atrophic scar histology : without epidermal acantholysis For pemphigus group : patient pemphigus For lupus group : systemic lupus patient : presence 4 diagnostic criterion systemic lupus erythematosus define American College Rheumatology ( amended 1997 ) characteristic subacute cutaneous lupus : clinical , histological immunological ( antiSSa ) clinical histological characteristic chronic lupus For control group : hospitalized patient history autoimmune , inflammatory evolve neoplastic disease The patient participate another study The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient pregnant , parturient , breastfeed For patient bullous pemphigoid , pemphigus lupus : The patient take systemic treatment The patient take topical steroid 15 day . For control : autoimmune disease inflammatory disease evolve neoplastic disease surgery last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>proteasomes</keyword>
	<keyword>proteasome concentration</keyword>
	<keyword>disease activity</keyword>
	<keyword>proteolytic activity</keyword>
	<keyword>autoantibody</keyword>
	<keyword>proteasome autoantibody</keyword>
</DOC>